$1.97
1.50% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
KYG108301006
Symbol
BYSI
Sector
Industry

BeyondSpring Inc. Stock price

$1.97
+0.16 8.84% 1M
-1.45 42.40% 6M
+1.07 118.89% YTD
+1.06 116.63% 1Y
-24.87 92.66% 3Y
-19.68 90.90% 5Y
-14.83 88.27% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.03 1.50%
ISIN
KYG108301006
Symbol
BYSI
Sector
Industry

Key metrics

Market capitalization $79.39m
Enterprise Value $72.63m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 38.63
P/S ratio (TTM) P/S ratio 42.23
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $1.88m
EBIT (operating result TTM) EBIT $-17.05m
EPS (TTM) EPS $-0.40
Short interest 8.95%
Show more

Is BeyondSpring Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

BeyondSpring Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BeyondSpring Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast BeyondSpring Inc.:

Buy
100%

Financial data from BeyondSpring Inc.

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
1.88 1.88
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.36 9.36
-
498%
- Research and Development Expense 9.57 9.57
-
509%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -17 -17
74% 74%
-907%
Net Profit -16 -16
-
-828%

In millions USD.

Don't miss a Thing! We will send you all news about BeyondSpring Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BeyondSpring Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announces that it will have an oral presentation on the final efficacy data of Plinabulin and docetaxel combination vs. docetaxel from Dublin-3 phase 3 study in EGFR w...
Neutral
GlobeNewsWire
about one month ago
SEED Concurrently Enters into Share Purchase Agreements for its Series A-3 Financing Led by Eisai SEED Concurrently Enters into Share Purchase Agreements for its Series A-3 Financing Led by Eisai
Neutral
GlobeNewsWire
4 months ago
FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it hosted a virtual Research and Development (R&D) Day to discuss its lead asset Plinabulin, a dendritic cell (DC) maturation agent, in drug combinations ...
More BeyondSpring Inc. News

Company Profile

BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.

Head office Cayman Islands
CEO Lan Huang
Employees 35
Founded 2010
Website www.beyondspringpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today